Financial Performance - As of June 30, 2022, the company had an accumulated deficit of $203.4 million and incurred net losses of $8.1 million for the first half of 2022[108]. - Revenue for the three months ended June 30, 2022, was $41,000, a decrease of 100% compared to $11,880,000 for the same period in 2021[132]. - Gross profit for the same period was $41,000, down 88% from $353,000 in the prior year[132]. - Revenues in Q2 2022 were $0.1 million, a decrease of $11.8 million, or 100%, from Q2 2021, primarily due to the wind-down of the soybean product line[133]. - Net loss improved to $2.5 million in Q2 2022, a reduction of $2.3 million, or 48%, from Q2 2021, aided by non-operating income[138]. - Adjusted net loss was $6.7 million in Q2 2022, an improvement of $1.2 million, or 15%, from Q2 2021, due to the completion of the soybean product line wind-down[139]. - The net loss for the Company was $8.1 million for the six months ended June 30, 2022[169]. - The Company reported a net loss of $2,485,000 for the three months ended June 30, 2022, compared to a net loss of $4,807,000 for the same period in 2021[186]. - Adjusted net loss for the six months ended June 30, 2022, was $12,655,000, a decrease from $16,693,000 for the same period in 2021[186]. - Adjusted net loss per share for the three months ended June 30, 2022, was $(0.14), compared to $(0.21) for the same period in 2021[188]. Research and Development - Research and development expenses increased by 14% to $3,250,000 from $2,844,000 year-over-year[132]. - R&D expenses increased to $3.3 million in Q2 2022, up $0.4 million, or 14%, from Q2 2021, driven by higher allocated SG&A costs[134]. - The company received nine new chemistries for evaluation in Q2 2022, bringing the total evaluated chemistries to 95, with 31 meeting the target product profile criteria[109]. - The company expects to produce small quantities of product for customer evaluation, potentially shortening the development cycle to less than 36 months[109]. - A pilot project for a high-value chemistry is expected to deliver an engineered solution in early 2023 for a large global consumer packaged goods company[111]. - The company anticipates that future revenues will primarily arise from product development activities and technology licensing arrangements, with strong positive gross profit margins expected over time[128]. Expenses and Cash Flow - SG&A expenses were $3.6 million in Q2 2022, an increase of $0.1 million, or 2%, from Q2 2021, influenced by higher stock compensation and lease accounting adjustments[135]. - Adjusted EBITDA loss was $4.8 million in Q2 2022, an improvement of $1.0 million, or 17%, from Q2 2021, reflecting operational adjustments[143]. - Net cash used by operating activities was $11.3 million in the first six months of 2022, flat compared to the same period in 2021[161]. - Cash used by investing activities increased by $12.7 million, or 111%, to $1.3 million in the first six months of 2022 compared to the same period in 2021[163]. - Net cash provided by financing activities was $10.1 million in the first six months of 2022, an increase of $10.0 million, or 20,427%, from the first six months of 2021[166]. - The Company expects cash used by operating activities in 2022 to be higher than in 2021 due to the elimination of the working capital benefit from the wind-down of the soybean product line[162]. - The Company expects cash provided by financing activities in 2022 to be higher than in 2021, driven by proceeds from the Follow-on Offering[167]. Capital and Financing - The company closed a Follow-On Offering in February 2022, raising gross proceeds of $10.9 million, with plans to use approximately $10.0 million for enhancing BioFactory capabilities and working capital[118]. - The Company completed a follow-on offering on February 23, 2022, raising net proceeds of $10.0 million by issuing 3,880,000 shares of common stock[158]. - The Company issued 3,880,000 shares of common stock in the Follow-On Offering, resulting in net proceeds of $10.0 million after expenses[171]. - The Company anticipates continuing to incur losses for the next several years and will need to raise additional capital to support its business plan[172]. - The Company plans to invest in scaling its BioFactory production system, which will increase capital expenditures in 2022[164]. Non-Operating Income and Adjustments - Non-operating income was $4.3 million in Q2 2022, an increase of $4.3 million, or 71,500%, from Q2 2021, driven by the mark-to-market of Common Warrants[137]. - Non-operating income (expenses) for the three months ended June 30, 2022, was $(4,296,000), compared to $(6,000) for the same period in 2021[192]. - The Company incurred Section 16 officer transition expenses of $116,000 for the three months ended June 30, 2022, compared to $13,000 for the same period in 2021[192]. - The Company recognized a gain upon extinguishment of the Payroll Protection Program loan of $(1,528,000) for the three months ended June 30, 2021[192]. - The Company adjusted for commodity derivative impacts, netting to $(658,000) for the three months ended June 30, 2021[192]. - The Company experienced a net realizable value adjustment to inventories of $(859,000) for the three months ended June 30, 2021[192]. Stock Price Volatility - The Company highlighted the volatility of its common stock price, which could significantly impact its net loss due to changes in the fair value of its common stock warrant liability[195].

| --- | --- | --- | |-------------------------------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | The Power of Plants | | | | Q2 2022 INVESTOR PRESENTATION | | | Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as "ant ...

Calyxt, Inc. (CLXT) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Bill Koschak - Chief Financial Officer Michael Carr - President and Chief Executive Officer Conference Call Participants Bobby Burleson - Canaccord Amit Dayal - H.C. Wainwright Brian Wright - ROTH Capital Partners Operator Good afternoon, ladies and gentlemen. Thank you for standing by. Welcome to Calyxt’s First Quarter 2022 Earnings Result Conference Call and Webcast. [Operator Instructions] This conference is ...

Table of Contents Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock (0.0001 par value) CLXT The NASDAQ Global Market Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022; or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the tran ...

| --- | --- | --- | --- | |--------------------------------------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 4Q and FY 2021 Earnings | | | | | Results Conference Call and Webcast | | | | | MARCH 3, 2022 | | | | Management on Today's Call Michael A. Carr President and Chief Executive Officer Bill Koschak Chief Financial Officer © calyxt 2 Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the ...

Calyxt, Inc. (CLXT) Q4 2021 Earnings Conference Call March 3, 2022 4:30 PM ET Company Participants Bill Koschak - Chief Financial Officer Michael Carr - President and CEO Conference Call Participants Laurence Alexander - Jefferies Bobby Burleson - Canaccord Brian Wright - ROTH Capital Partners Amit Dayal - H.C. Wainwright Operator Good afternoon, ladies and gentlemen. Thank you for standing by. Welcome to Calyxt Fourth Quarter and Full Year 2021 Earnings Conference -- Result Conference Call and Webcast. Dur ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021; or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38161 Calyxt, Inc. (Exact name of registrant as specified in its charter) Delaware 27-1967997 (State or other juri ...

Calyxt, Inc. (CLXT) Q3 2021 Earnings Conference Call November 4, 2021 4:30 PM ET Company Participants Bill Koschak - Chief Financial Officer Michael Carr - President & Chief Executive Officer Travis Frey - Chief Technology Officer Conference Call Participants Bobby Burleson - Canaccord Genuity Brian Wright - Roth Capital Partners Sameer Joshi - H.C. Wainwright & Co. Operator Good afternoon, ladies and gentlemen. Thank you for standing by. Welcome to Calyxt Third Quarter 2021 Earnings Result Conference Call ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock (0.0001 par value) CLXT The NASDAQ Global Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021; or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition perio ...

Calyxt, Inc. (CLXT) Q2 2021 Earnings Conference Call August 5, 2021 4:30 PM ET Company Participants Cameron Willis - Assistant Vice President of Argot Partners, Investor Relations, Calyxt Yves Ribeill - Executive Chair of the Board Michael Carr - President & Chief Executive Officer Bill Koschak - Chief Financial Officer Conference Call Participants Laurence Alexander - Jefferies Bob Burleson - Canaccord Genuity Sameer Joshi - H.C. Wainwright Operator Good afternoon, ladies and gentlemen, and thank you for s ...